
Telmisartan (40mg) + Metoprolol Succinate (25mg) + Chlorthalidone (12.5mg)
Active composition
+2 more active ingredients
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Metosartan CH 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes sodium and water excretion, reducing blood volume and peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing cardiac workload. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased systemic vascular resistance. The combined pharmacological actions of these agents provide complementary mechanisms to effectively manage hypertension, reduce the risk of cardiovascular events, and improve patient outcomes. Metosartan CH 25 Tablet ER is indicated for patients requiring multi-drug therapy to achieve optimal blood pressure control. It should be administered under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes. Caution is advised in patients with renal impairment, electrolyte imbalances, or contraindications to any component.
How to use Metosartan CH Tablet ER Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Metosartan CH 25 Tablet ER may be taken with or without food, but it is better to take it at a fixed time.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
It is unsafe to consume alcohol with Metosartan CH 25 Tablet ER.
High Risk
Metosartan CH 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Medical Advice
Metosartan CH 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Exercise Caution
Metosartan CH 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Metosartan CH 25 Tablet ER may be needed. Please consult your doctor. Use of Metosartan CH 25 Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
Metosartan CH 25 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Metosartan CH 25 Tablet ER should be used with caution in patients with severe kidney disease. Dose adjustment of Metosartan CH 25 Tablet ER may be needed. Please consult your doctor. Use of Metosartan CH 25 Tablet ER is not recommended in these patients.
Regular Checkup
0 reviews for Metosartan CH 25 Tablet ER

Chlorthalidone (12.5mg) + Metoprolol Succinate (25mg) + Telmisartan (40mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Metosartan CH 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes sodium and water excretion, reducing blood volume and peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing cardiac workload. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased systemic vascular resistance. The combined pharmacological actions of these agents provide complementary mechanisms to effectively manage hypertension, reduce the risk of cardiovascular events, and improve patient outcomes. Metosartan CH 25 Tablet ER is indicated for patients requiring multi-drug therapy to achieve optimal blood pressure control. It should be administered under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes. Caution is advised in patients with renal impairment, electrolyte imbalances, or contraindications to any component.
How to use Metosartan CH Tablet ER Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Metosartan CH 25 Tablet ER may be taken with or without food, but it is better to take it at a fixed time.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
It is unsafe to consume alcohol with Metosartan CH 25 Tablet ER.
High Risk
Metosartan CH 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Medical Advice
Metosartan CH 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Exercise Caution
Metosartan CH 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Metosartan CH 25 Tablet ER may be needed. Please consult your doctor. Use of Metosartan CH 25 Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
Metosartan CH 25 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Metosartan CH 25 Tablet ER should be used with caution in patients with severe kidney disease. Dose adjustment of Metosartan CH 25 Tablet ER may be needed. Please consult your doctor. Use of Metosartan CH 25 Tablet ER is not recommended in these patients.
Regular Checkup
0 reviews for Metosartan CH 25 Tablet ER















